Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
about
The evolving role of response-adapted PET imaging in Hodgkin lymphomaSystematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapyThe role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseasePediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessmentThe predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scaleThe Evolving Role of Radiotherapy in Early Stage Hodgkin's Lymphoma.Positron Emission Tomography (PET) in OncologyDiagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma.Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG PET/CT in extra-nodal NK/T-cell lymphoma.Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy.When should FDG-PET be used in the modern management of lymphoma?Current role of FDG PET/CT in lymphoma.Role of PET in lymphoma.Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome.Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma.Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.PET-directed therapy in Hodgkin lymphoma: Ready for prime time?Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of (18)FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria.Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients.The role of FDG-PET in Hodgkin lymphomaFDG-PET in Follicular Lymphoma ManagementInterim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies.Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma.Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine.The predictive value of interim FDG-PET in early-stage Hodgkin lymphoma is not well established.Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".Will treatment intensification in early-stage Hodgkin lymphoma patients with a positive interim FDG-PET improve outcome?Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy.
P2860
Q26750993-8B24532A-F23B-4A81-972D-A8C0614F73B9Q26781731-970F7F60-2966-4480-9CB3-0B7363321767Q26858893-21DF84F0-25B5-4C31-9B91-3FA550502160Q30363610-0DE33607-EDEF-4AF1-9FBC-FE7440577394Q33696003-C1DDAF20-DCED-4C54-9318-D2AECE84A0BCQ33778385-B3CC0B31-F911-48AB-AC5F-7707F361F682Q34774840-480F7441-30D3-4CC4-8E4C-36EA8538A45AQ36429831-3E46739D-C110-4F9D-BBE7-3B73C95EA87BQ36897012-658D8DFA-B82C-4EBC-B600-FB7D5D92A720Q37144956-B4D9774D-7BF0-492A-9B9A-1B6384AE2A22Q37240835-E3A8D94B-55D1-47C5-B50C-4879F4D426E8Q37641042-228C6CD6-616F-4D8E-9BA1-33BED344766AQ37702163-5EA08210-77C6-4DE5-A2E1-C11B65E9DDB5Q38049331-628CB9FE-2762-4484-8BC1-EE6FCF56CA89Q38153086-C6C09DC3-EBE2-4CC0-BF06-57CB87E03A33Q38187365-A8595A60-A412-427D-82E1-CA315AD839F2Q38195220-D65426F5-A1BF-4277-A159-BFD1D1632FD4Q38285627-A59DFCBB-1ECF-4719-8B6F-D5C8AB5988D0Q38365591-EDB3F9AC-5E09-4C3C-A3F1-940DC0B656D0Q38389152-60CC1D78-0D1C-49D8-9241-7CC453478FE4Q38410048-431CDE2A-EC91-4040-AACB-9C6483F2D8F0Q38418605-780CDD27-2A78-4F26-9461-E9A0364BF87AQ38549745-20043F1A-2FCA-441B-B90D-F45FB3F42E50Q38608555-A843D51B-CF94-4B9A-BE35-8134AFB44562Q38663136-D71136A1-95CC-4094-8567-D1739C7C8ABEQ38716320-555B3FB5-0071-4D7E-836F-46188EABDF9CQ38836081-EF21B7AB-A5CD-4ADD-B8DB-52FFF53D6D60Q39675210-D8437DD0-4699-403E-AEB1-56088E110882Q41691698-444D42B2-3C22-4FC2-9660-0F10EA6BE342Q41840128-01FD2EFD-FE28-4713-92A4-1C890F35970DQ44635336-F96F749E-C13D-4867-BEF3-174063B987AAQ44750052-C0A374E9-715A-4B1C-8652-24F1693ED25AQ45428337-61B9A3D3-5450-4F8C-8B30-4DC67F7F73FBQ47149857-294418C2-BF59-4AB3-8609-3AFED2EED754Q48127652-7EE4852B-3CBE-4963-9565-0800634E4AADQ48139391-783EF787-F1F0-4A63-B4C6-80D95C85043AQ50089452-5C072385-0005-467C-92C3-6A5363D01331Q52937933-23DEEB5F-75A0-419E-9B57-E6619D57D0ECQ52984779-D08A916E-1CE7-49E9-AAC6-E60873382E9BQ53059192-0C25D9F5-53BA-4529-A10E-BC8D25635F4C
P2860
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
description
im Jahr 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2012
@uk
name
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
@en
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
@nl
type
label
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
@en
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
@nl
prefLabel
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
@en
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
@nl
P2093
P2860
P1476
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
@en
P2093
Alessandro Broccoli
Antonio Castagnoli
Benedetta Puccini
Lisa Argnani
Luca Vaggelli
Lucia Zanoni
Luigi Rigacci
Stefano Fanti
Vittorio Stefoni
P2860
P2888
P356
10.1007/S00259-011-1916-8
P407
P577
2012-01-01T00:00:00Z